Riskpilot← Back to searchSign inGet full accessMEDICUM UTVIKLING AS
ASActiveOrg 912882764Thomasbakkveien 95, 9513 AltaDevelopment of building projects · NACE 6812Est. 20141 employees
Revenue 2025
NOK 158K
0% vs 2024
EBITDA margin
21.2%
+171% vs 2024
Equity ratio
92.6%
Financial strength
Net profit 2025
NOK 49K
+246% vs 2024
| Revenue | NOK 158K | +0% |
| EBITDA | NOK 34K | +171% |
| Net profit | NOK 49K | +246% |
| Total assets | NOK 1,4M | +1% |
| Equity | NOK 1,3M | +4% |
| Employees | 1 | — |
Legal name
MEDICUM UTVIKLING AS
Org number
912882764
Legal form
Aksjeselskap
NACE code
6812 · Development of building projects
Founded
3. januar 2014
Share capital
NOK 30 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Daglig leder alene.
Company purpose
Kjøp, salg og eie av aksjer og eiendom og andre produkter som naturlig hører sammen med dette, herunder å delta i andre selskap med lignende virksomhet, og kjøp og salg av aksjer eller på annen måte gjøre seg interessert i andre foretak.
Address
Thomasbakkveien 95, 9513 Alta
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 320 | 158 | 158 | 158 | 158 |
| Staff expenses | −208 | −107 | −141 | −112 | −56 |
| EBITDA | 22 | −63 | −46 | −47 | 34 |
| Depreciation & amort. | −26 | −0 | −0 | −0 | −0 |
| EBIT | −4 | −63 | −46 | −47 | 34 |
| Net financials | 0 | 1 | 5 | 14 | 15 |
| Profit before tax | −4 | −62 | −41 | −33 | 49 |
| Tax | 7 | −0 | −0 | −0 | −0 |
| Net profit | −11 | −62 | −41 | −33 | 49 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 530 | 1 375 | 1 317 | 1 366 | 1 383 |
| Equity | 1 368 | 1 306 | 1 266 | 1 232 | 1 281 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 162 | 69 | 52 | 134 | 102 |
| Total debt | 162 | 69 | 52 | 134 | 102 |
EBITDA margin
21.2%
This company
15.8%
Market median
+34% vs market
20212025
Equity ratio
92.6%
This company
38.2%
Market median
+142% vs market
20212025
Return on equity
3.8%
This company
18.4%
Market median
-79% vs market
20212025
Net profit margin
30.9%
This company
8.1%
Market median
+281% vs market
20212025
Asset turnover
0.11×
This company
1.12×
Market median
-90% vs market
20212025
Debt / equity
0.08×
This company
0.62×
Market median
+87% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
IL Chief Executive Officer | Chief Executive Officer | 2016 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2014 | |
| Board of Directors | 2014 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of MEDICUM UTVIKLING AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ivar Leinan | Chief Executive Officer | 0 companies |
| Tone Leinan | Chairman | 0 companies |
| Irene Leinan | Board of Directors | 0 companies |